BITRF
Biotron Limited is an Australian biotechnology firm focused on the development and market introduction of small-molecule compounds designed to combat various viral infections. The company's primary antiviral agent, BIT225, is currently undergoing Phase II clinical trials to assess its efficacy against SARS-CoV-2, HIV-1, and hepatitis C virus infections. Founded in 1999, Biotron Limited's main offices are situated in Sydney, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | 0.00 | $0 | -$868,078 |
| 2025 Q4 | -0.00 | -$868 | -$1M |
| 2024 Q2 | 0.00 | $2M | $486,396 |
| 2024 Q4 | -0.00 | $0 | -$307,478 |
| 2023 Q2 | -0.00 | $2M | -$3M |
| 2023 Q4 | -0.00 | $0 | -$2M |
| 2022 Q2 | -0.00 | $1M | -$821,974 |
| 2022 Q4 | -0.00 | $779,263 | -$597,374 |